Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced that it has completed a private placement with U.S. institutional investors totalling €5.54 million. Directly following the U.S. capital increase, the Company raised an additional €3.04 million through a public offering in Europe through existing shareholders, for a total of €8.6 million.
[button link=”http://www.quantum-genomics.com/www/wp-content/uploads/2016/03/Quantum-Genomics-US-Capital-Increase-VF1.pdf” target=”_blank” title=”Download Press Release” size=”small” color=”red”]
